The expert panel of the U.S. Department of Health and Human Services recommends starting antiretroviral therapy (ART) as soon as possible after HIV is diagnosed, regardless of CD4 count. Most people starting HIV treatment for the first time (treatment-naïve) should take one of the following: Biktarvy; Dovato; Triumeq; Tivicay plus Descovy or Truvada; or Isentress HD or Isentress with Descovy or Truvada. Go to hivinfo.nih.gov for more information.
Rating of recommendations
- Strong
- Moderate
- Optional
Rating of evidence
- Data from randomized controlled trials.
- Data from well-designed non-randomized trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomized switch studies.
- Expert opinion.
The following are available as co-formulated drugs
(Not a complete list)
- Atripla: EFV/FTC/TDF
- Biktarvy: BIC/FTC/TAF
- Cimduo or Temixys: 3TC/TDF
- Complera: RPV/FTC/TDF
- Delstrigo: DOR/3TC/TDF
- Descovy: FTC/TAF
- Dovato: DTG/3TC
- Epzicom: ABC/3TC
- Evotaz: ATV/c
- Genvoya: EVG/c/FTC/TAF
- Odefsey: RPV/FTC/TAF
- Prezcobix: DRV/c
- Stribild: EVG/c/FTC/TDF
- Symfi: EFV 600 mg/3TC/TDF
- Symfi Lo: EFV 400 mg/3TC/TDF
- Symtuza: DRV/c/FTC/TAF
- Triumeq: DTG/ABC/3TC
- Truvada: FTC/TDF
